🏛️ Verified NIH Record • Updated 2026-08-10
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome (NCT05535361)
🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Eclipse Regenesis, Inc.
🩺 Plain-English Summary (8th-Grade Level)
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
Who can join: Review the eligibility criteria below.
Location: Lucile Packard Children's Hospital Stanford — Palo Alto, California
Age range: 3 Months to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Lucile Packard Children's Hospital Stanford — Palo Alto, California
- University of California San Francisco — San Francisco, California
- Children's National Hospital — Washington D.C., District of Columbia
- Boston Children's Hospital — Boston, Massachusetts
- Cincinnati Children's Hospital — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (617) 249-0955
Email: andre@eclipseregenesis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Short Bowel Syndrome
- Registry for Participants With Short Bowel Syndrome — Lexington, Massachusetts
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS — Washington D.C., District of Columbia
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial — Washington D.C., District of Columbia
- Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome — Cleveland, Ohio
- Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Los Angeles, California
Explore by condition: All Short Bowel Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.